Compare RGEN & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | G |
|---|---|---|
| Founded | 1981 | 1997 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.2B |
| IPO Year | N/A | 2007 |
| Metric | RGEN | G |
|---|---|---|
| Price | $163.11 | $45.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $177.18 | $51.00 |
| AVG Volume (30 Days) | 600.1K | ★ 1.2M |
| Earning Date | 02-19-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.48% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.03 | ★ 3.10 |
| Revenue | $707,890,000.00 | ★ $5,009,342,000.00 |
| Revenue This Year | $17.86 | $8.47 |
| Revenue Next Year | $12.44 | $6.90 |
| P/E Ratio | $5,247.54 | ★ $14.81 |
| Revenue Growth | ★ 11.74 | 7.39 |
| 52 Week Low | $102.97 | $37.49 |
| 52 Week High | $182.52 | $56.76 |
| Indicator | RGEN | G |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 44.18 |
| Support Level | $158.80 | $46.35 |
| Resistance Level | $172.51 | $47.91 |
| Average True Range (ATR) | 6.24 | 0.98 |
| MACD | -0.83 | -0.30 |
| Stochastic Oscillator | 25.84 | 15.20 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.